NCT02662725已完成2 期
A Multicenter Phase II Study of Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases
University Hospital, Lille17 个研究点 分布在 1 个国家目标入组 73 人开始时间: 2012年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 73
- 试验地点
- 17
- 主要终点
- Overall survival rate
研究概览
简要总结
This is a non-controlled, open label, Phase II Study of ipilimumab combined with a Stereotactic Radiosurgery. The study included an induction phase of four IV infusions of Ipilimumab at 10 mg/kg every 3 weeks associated with a stereotactic radiosurgery performed 3 days before 2nd ipilimumab administration. A Maintenance phase included Ipilimumab, IV, 10 mg/kg once every 12 weeks, starting at week 24, in the absence of PD, unacceptable toxicity or withdrawal of consent or disease progression. The primary objective is the overall survival. The Secondary objectives include safety, ORR, PFS and peripheral blood absolute lymphocyte count (ALC) as a predictive biomarker.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to give written informed consent.
- •Men and women ≥ 18 years of age.
- •Patient eligible to single dose Stereotactic Radiotherapy (Radiosurgery) as per the pluridisciplinary committee.
- •Neurologically asymptomatic or pauci-symptomatic patients. Patients with moderated neurological symptoms without systemic corticosteroids treatment can be included.
- •Less than 4 brain metastasis at the MRI. Brain metastasis should measure less than 3 cm in diameter. At least one brain metastasis > 5mm.
- •Maximum one prior systemic therapy for metastatic disease is allowed.
- •Prior treatment with INTERFERON in the adjuvant setting is authorized. Prior treatment with anti-CTLA-4 is NOT authorized.
- •ECOG Performance Status 0 or 1
- •Within the last 2 weeks prior to study day 1 the following laboratory parameters, which should be within the ranges specified:
排除标准
- •The patient requires concomitant chronic treatment with systemic corticosteroids or any other immunosuppressive agents 7 days prior to inclusion.
- •Neurological symptoms treated with systemic corticosteroids (whatever the dose of corticoids).
- •The patient has concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk such as but not limited to: Cardiac insufficiency (III or IV as per NYHA classification), Renal insufficiency, ongoing infection.
- •Any symptom of concomitant tumour meningitis
- •History of immediate or delayed gadolinium hypersensitivity, or any contraindication to undergo MRI examination (Pacemaker, brain aneurysms clips)
- •Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix (Subjects with a previous malignancy but without evidence of disease for 5 years will be allowed to enter the study)
- •Uncontrolled infectious diseases - requires negative tests for clinically suspected HIV, HBV and HCV. If positive results are not indicative of true active or chronic infection, the subject may enter the study after discussion and agreement between the Investigator and the Medical Monitor.
- •Active autoimmune disease. Autoimmune disease: subjects with a documented history of inflammatory bowel disease, including ulcerative colitis and Crohn's disease are excluded from this study as are subjects with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], Systemic Lupus Erythematosus, autoimmune vasculitis [e.g., Wegener's Granulomatosis]).
- •Subjects with motor neuropathy considered of autoimmune origin (e.g., Guillain Barré Syndrome) are excluded from this study
- •Previous treatment with a CTLA-4 antagonist agent, including treatment in adjuvant setting.
- •The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent or to comply with the trial procedures.
- •Lack of availability for clinical follow-up assessments.
- •For female patients: the patient is pregnant or lactating.
- •Women of childbearing potential: refusal or inability to use effective means of contraception
- •Participation in another clinical trial protocol within 30 days prior to enrolment
- •Persons protected by a legal regime (guardianship, trusteeship)
- •Patients in emergency situations
- •Patients kept in detention
研究组 & 干预措施
ipilimumab + Stereotactic Radiosurgery
Experimental
ipilimumab combined with a Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases
干预措施: IPILIMUMAB (Drug)
ipilimumab + Stereotactic Radiosurgery
Experimental
ipilimumab combined with a Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases
干预措施: Stereotactic radiosurgery (Radiation)
结局指标
主要结局
Overall survival rate
时间窗: until week 96 or death
次要结局
- All adverse events ≥ Grade 3 according to CTCAE, Version 4.0 criteria,(through study completion, until week 96)
- Overall response rate in brain(until week 96 or death)
- Global overall response rate(until week 96 or death)
- Disease control rate in brain(until week 96 or death)
- Global disease control rate(until week 96 or death)
- Progression free survival(until week 96 or death)
研究者
研究点 (17)
Loading locations...
相似试验
招募中
2 期
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)NCT03340129Melanoma Institute Australia218
已完成
2 期
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADTProstatic NeoplasmsNCT03007732David Oh23
进行中（未招募）
2 期
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung CancerNCT03110978M.D. Anderson Cancer Center140
终止
2 期
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced MelanomaMelanomaNCT01709162Bristol-Myers Squibb31
已完成
2 期
An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by ItselfMelanomaNCT02320058Bristol-Myers Squibb119